

REMARKS

Applicants gratefully acknowledge the Office Action mailed October 29, 2003 indicating that claims 1-24 are in condition for allowance.

AMENDMENT TO SEQUENCE LISTING

The Examiner has stated that the peptide sequences on page 22, lines 13 and 15 do not have corresponding SEQ ID Nos. The peptide sequence on page 22, line 13 is a generic Zn binding sequence His Glu X X His, where X is any amino acid. The sequences at line 15 are species of this generic sequence. These sequences have been added as SEQ ID NOs 12-15.


Accordingly, Applicants hereby submit a substitute sequence listing, both in paper and CRF (floppy disc) formats. The following statements are made in compliance with 37 CFR 1.825(a) and (b): The substitute sheets of the sequence listing contain no new matter, and the information contained in the accompanying CRF is the same as in the paper copy of the substitute sequence listing.

CONCLUSION

For the reasons given above, Applicants believe all the pending claims are in condition for allowance, and respectfully request that the Examiner issue a Notice to that effect. If any fee is required in connection with this communication; please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,

Date: 12/22/03



Carlos A. Fisher  
Reg. No. 36,510  
ALLERGAN, INC.  
T2-7H  
2525 Dupont Drive  
Irvine, CA 92612  
Tel: 714-246-4920  
Fax: 714-246-4249